News

Article

Gyros Protein Technologies and Cygnus Technologies to Develop Impurity Reagent Sets

The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells.

Continuing their collaboration, Gyros Protein Technologies and Cygnus Technologies introduce a new HEK 293 host cell protein (HCP) immunoassay solution. The Cygnus HEK 293 HCP Assay Reagent Set for Gyrolab, a planned ready-to-use bioprocess impurity reagent, uses the Gyrolab platform, which will be developed by Cygnus.

The two companies’ previous collaboration yielded a successful launch of the ready-to-use Gyrolab CHO, HCP, and Escherichia coli HCP kits. Now, the companies are expanding the partnership to develop ready-to-use bioprocess impurity reagent sets.

The immunoassay solution is designed for use with the Gyrolab Bioaffy 1000HC Toolbox. It detects residual HCP from HEK 293 cells and is often used in viral vector production for cell and gene therapies as well as for manufacturing vaccines.

Source: Gyros Protein

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content